REGULATORY

Drug Pricing Organization to Price JCR’s Cell Therapy Temcell

October 1, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) agreed on September 30 that the reimbursement price of JCR Pharmaceuticals’ recently approved cell-based therapy will be set by the Drug Pricing Organization as the product has characteristics close to those of pharmaceuticals.…

To read the full story

Japan Approves JCR Pharma’s Cell-Based Acute GVHD Treatment
September 24, 2015
Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
September 24, 2015

REGULATORY

Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
February 26, 2026
LDP Panel Delays Approval of Health Insurance Bill amid Concerns over OTC-Like Drug Charges
February 26, 2026
MHLW Orders Colchicine Label Revision, Warns against Doses above 1.5 mg per Day
February 26, 2026
Symbicort Switch to OTC Status Gains No Support at MHLW Panel
February 25, 2026
Japan Govt Council Finalizes Recommendations for National MCM Strategy
February 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…